{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:08:45Z","timestamp":1788930525644,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases. It is characterized by an exceptionally high proliferative rate, a strong propensity for early metastasis, and a poor prognosis. The median overall survival (OS) following brain metastases development in extensive-stage SCLC (ES-SCLC) was 10.5 months. Herein, a 74-year-old Chinese male was initially diagnosed with ES-SCLC with synchronous hepatic metastases. Following four cycles of first-line chemotherapy comprising etoposide and carboplatin, the patient underwent thoracic radiotherapy (TRT); however, prophylactic cranial irradiation was not performed. Brain metastases were detected 19 months after TRT, prompting initiation of palliative whole-brain RT (WBRT). Intracranial disease recurrence was observed five months after completion of WBRT. Managing intracranial recurrence following palliative WBRT in patients with ES-SCLC is clinically challenging. In this case of intracranial recurrence following palliative WBRT, the patient received second-line therapy comprising tislelizumab in combination with irinotecan and cisplatin chemotherapy, followed by anlotinib as maintenance therapy, achieving a complete response, sustained status of no evidence of disease for 24 months, and an OS of 67 months. Based on this case, tislelizumab combined with chemotherapy followed by anlotinib maintenance therapy represents a potentially viable treatment strategy for patients with recurrent intracranial lesions following palliative WBRT who have not received prior immune checkpoint inhibitor therapy. However, given the limited evidence derived solely from a single case, the clinical utility of this regimen requires validation in prospective and controlled trials.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1937771","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:41:13Z","timestamp":1788928873000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tislelizumab plus chemotherapy followed by anlotinib maintenance therapy in a patient with extensive-stage small cell lung cancer and intracranial recurrence after palliative whole-brain radiotherapy: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Rong","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shaoxing Second Hospital","place":["Shaoxing, Zhejiang, China"]},{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xialin","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]},{"name":"Department of Oncology, Shaoxing People\u2019s Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lang","sequence":"additional","affiliation":[{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]},{"name":"Department of Pathology, Shaoxing People\u2019s Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkui","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shaoxing Second Hospital","place":["Shaoxing, Zhejiang, China"]},{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12123629","article-title":"Systematic review and network meta-analysis of immune checkpoint inhibitors in combination with chemotherapy as a first-line therapy for extensive-stage small cell carcinoma","volume":"12","author":"Chen","year":"2020","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/crj.70107","article-title":"Comprehensive analysis of lung cancer metastasis: Sites, rates, survival, and risk factors-a systematic review and meta-analysis","volume":"19","author":"Wang","year":"2025","journal-title":"Clin Respir J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1191855","article-title":"Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study","volume":"13","author":"Dawe","year":"2023","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10644","article-title":"Prognostic effect of liver metastasis in lung cancer patients with distant metastasis","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.008","article-title":"Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial","volume":"19","author":"Cheng","year":"2024","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102795","article-title":"Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC): a phase II trial","volume":"75","author":"Chen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/cco-21-108","article-title":"Radiation therapy in the prevention and management of brain metastases in patients with small cell lung cancer: a narrative review","volume":"11","author":"Hau","year":"2022","journal-title":"Chin Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jtho.2020.09.013","article-title":"American radium society appropriate use criteria on radiation therapy for extensive-stage SCLC","volume":"16","author":"Higgins","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0360-3016(91)90010-2","article-title":"Radiation injury of the brain","volume":"12","author":"Valk","year":"1991","journal-title":"AJNR Am J Neuroradiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.sult.2023.03.004","article-title":"Morphological and functional neuroradiology of brain metastases","volume":"44","author":"Grazzini","year":"2023","journal-title":"Semin Ultrasound CT MR"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad188","article-title":"The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases","volume":"26","author":"Mayo","year":"2024","journal-title":"Neuro Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13847","article-title":"Differentiation between radiation necrosis and true tumour progression after radiotherapy to intracranial metastases","volume":"69","author":"Lasocki","year":"2025","journal-title":"J Med Imaging Radiat Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jmir.2019.10.001","article-title":"Should stereotactic radiosurgery be considered for salvage of intracranial recurrence after prophylactic cranial irradiation or whole brain radiotherapy in small cell lung cancer? A population-based analysis and literature review","volume":"51","author":"Fairchild","year":"2020","journal-title":"J Med Imaging Radiat Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3892\/ol.2022.13454","article-title":"Long-term survival in a patient with extensive-stage small cell lung cancer treated with multiple courses of salvage stereotactic radiation after whole brain radiotherapy: a case report","volume":"24","author":"Vucetic","year":"2022","journal-title":"Oncol Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_185_22","article-title":"Effectivity of involved-field radiotherapy for recurrent brain metastasis in patients with small-cell lung cancer","volume":"18","author":"Wang","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrt006","article-title":"Three-fraction CyberKnife radiotherapy for brain metastases in critical areas: referring to the risk evaluating radiation necrosis and the surrounding brain volumes circumscribed with a single dose equivalence of 14 Gy (V14)","volume":"54","author":"Inoue","year":"2013","journal-title":"J Radiat Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/clep.s546282","article-title":"A multi-country study of the clinical course of extensive-stage small cell lung cancer: a six-study analysis of real-world treatment patterns and outcomes","volume":"17","author":"Pundole","year":"2025","journal-title":"Clin Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.02.005","article-title":"Lurbinectedin plus pembrolizumab in relapsed SCLC: the phase I\/II LUPER study","volume":"20","author":"Calles","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-24-769","article-title":"Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study","volume":"16","author":"Wang","year":"2024","journal-title":"J Thorac Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1591643","article-title":"Real-world analysis of immunochemotherapy in recurrent small-cell lung cancer: opportunities for second-line approaches","volume":"16","author":"Guo","year":"2025","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103502","article-title":"Efficacy and safety of tislelizumab plus anlotinib and irinotecan as second-line treatment for extensive-stage small cell lung cancer: a single-arm, open-label, phase II trial","volume":"88","author":"Chen","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10238-025-01606-1","article-title":"Efficacy and safety analysis of atezolizumab continuation beyond progression in extensive-stage small cell lung cancer","volume":"25","author":"Shi","year":"2025","journal-title":"Clin Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1462581","article-title":"Efficacy and safety of anlotinib as maintenance treatment in extensive-stage small cell lung cancer: a single-armed single center retrospective study","volume":"14","author":"Xiong","year":"2024","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1186\/s12885-025-14458-5","article-title":"Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"O'Brien","year":"2006","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.04.017","article-title":"A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers","volume":"189","author":"Wang","year":"2026","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2016.04.006","article-title":"Evaluating changes to blood-brain barrier integrity in brain metastasis over time and after radiation treatment","volume":"9","author":"Murrell","year":"2016","journal-title":"Transl Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"109633","DOI":"10.1016\/b978-0-12-801076-1.00010-1","article-title":"Radiotherapy opens the blood-brain barrier and synergizes with anlotinib in treating glioblastoma","volume":"183","author":"Li","year":"2023","journal-title":"Radiother Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.radonc.2017.08.006","article-title":"Blood-tumor barrier opening changes in brain metastases from pre to one-month post radiation therapy","volume":"125","author":"Teng","year":"2017","journal-title":"Radiother Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.06.043","article-title":"Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultrastructural changes","volume":"66","author":"Yuan","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665072","article-title":"Advancements in consolidative thoracic radiotherapy following first-line immunotherapy in conjunction with chemotherapy for extensive-stage small cell lung cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/15330338251317571","article-title":"Anlotinib as maintenance therapy after first-line chemotherapy combined with consolidation radiation for extensive-stage small cell lung cancer","volume":"24","author":"Ma","year":"2025","journal-title":"Technol Cancer Res Treat"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1937771\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:41:27Z","timestamp":1788928887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1937771\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1937771"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1937771","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1937771"}}